JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
159actual
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-03
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-02 | actual | When the study began enrolling |
| Primary completion | 2024-09-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2024-09-12 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-07 | actual | When this record first appeared on the registry |
| Results posted | 2026-09-03 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neck Lines
Interventions
- Device: VOLITE XC — also filed as JUVÉDERM® VOLITE™ XC, SKINVIVE by JUVÉDERM®, JUVÉDERM® VOLITE™
- Device: VOLITE XC — also filed as JUVÉDERM® VOLITE™ XC, SKINVIVE by JUVÉDERM®, JUVÉDERM® VOLITE™
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving "Responder" Status Based on Evaluating Investigator's (EI) Live Assessment of Transverse Neck Lines Using the Allergan Transverse Neck Lines Scale (ATNLS)
measured Month 1
Number of Participants With Treatment-Emergent Adverse Events
measured Baseline to end of study (up to 14 Months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-05-28 · 4.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-10-07 · 540 KB · SAP_001.pdf
Related
ABBV · their whole pipeline · Who in Congress owns ABBV? · Executive-branch trades in ABBV
ABBV's other studiesmost recently updated first
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Phase 3 · Recruiting
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Phase 1/2 · Recruiting
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years Phase 3 · Recruiting
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Phase 3 · Recruiting
- Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis Phase 2 · Recruiting
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed